source
- Sanofi explores acquisition of Insmed in potential major biopharma dealSanofi is reportedly evaluating a purchase of the U.S. drugmaker Insmed, according to a Bloomberg News report. The potential transaction would rank among the largest biopharma acquisitions in rece…
- FDA approves Regeneron's siRNA drug Livsayis for myasthenia gravis, expanding its neurology portfolioRegeneron has received FDA clearance for its siRNA‑based therapy cemdisiran, now marketed as Livsayis, to treat myasthenia gravis. This approval is the second new myasthenia gravis drug cleared by…